These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29684141)

  • 21. Primary resistance of HIV to antiretrovirals among individuals recently diagnosed at voluntary counselling and testing centres in the metropolitan region of Recife, Pernambuco.
    Cavalcanti AM; Brito AM; Salustiano DM; Lima KO; Silva SP; Diaz RS; Lacerda HR
    Mem Inst Oswaldo Cruz; 2012 Jun; 107(4):450-7. PubMed ID: 22666853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
    Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
    J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results.
    Rodrigues R; Vazquez CM; Colares JK; Custodio RM; Bonásser Filho F; Souza Ldo R; Gianna MC; Marques CC; Brígido LF
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):97-102. PubMed ID: 15867972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
    Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
    J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proviral DNA as a Target for HIV-1 Resistance Analysis.
    Lübke N; Di Cristanziano V; Sierra S; Knops E; Schülter E; Jensen B; Oette M; Lengauer T; Kaiser R
    Intervirology; 2015; 58(3):184-9. PubMed ID: 26139571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
    Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
    J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.
    Cerqueira DM; Amorim RM; Silva RR; Camara GN; Brígido MM; Martins CR
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):877-82. PubMed ID: 15761606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads.
    Boukli N; Boyd A; Collot M; Meynard JL; Girard PM; Morand-Joubert L
    J Antimicrob Chemother; 2018 Nov; 73(11):3129-3136. PubMed ID: 30137336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005.
    Romero A; Sued O; Puig T; Esteve A; Pumarola T; Casabona J; González V; Matas L; Tural C; Rodrigo I; Margall N; Domingo P; Casanova A; Ferrer E; Caballero E; Ribera E; Farré J; Puig T; Amengual MJ; Navarro G; Prat JM; Masabeu A; Simó JM; Villaverde CA; Barrufet P; Sauca MG; Ortin X; Ortí A; Navarro R; Euras JM; Vilaró J; Villà MC; Montull S; Vilanova C; Pujol F; Díaz O; Miró JM;
    Enferm Infecc Microbiol Clin; 2011; 29(7):482-9. PubMed ID: 21543135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type.
    Teyssou E; Soulie C; Fauchois A; Palich R; Nouchi A; Sayon S; Abdi B; Wirden M; Katlama C; Pourcher V; Marcelin AG; Calvez V
    J Antimicrob Chemother; 2024 Jul; 79(7):1673-1676. PubMed ID: 38804140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.